Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) by 118.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,158 shares of the company’s stock after acquiring an additional 14,179 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Harmony Biosciences were worth $1,441,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HRMY. JPMorgan Chase & Co. raised its holdings in Harmony Biosciences by 13.5% during the first quarter. JPMorgan Chase & Co. now owns 25,343 shares of the company’s stock worth $1,234,000 after purchasing an additional 3,017 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Harmony Biosciences by 9.0% during the first quarter. Bank of New York Mellon Corp now owns 217,304 shares of the company’s stock worth $10,572,000 after purchasing an additional 17,893 shares in the last quarter. Citigroup Inc. grew its position in shares of Harmony Biosciences by 19.1% during the first quarter. Citigroup Inc. now owns 25,172 shares of the company’s stock worth $1,225,000 after acquiring an additional 4,030 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Harmony Biosciences by 69.7% during the first quarter. Acadian Asset Management LLC now owns 3,367 shares of the company’s stock worth $163,000 after acquiring an additional 1,383 shares during the last quarter. Finally, MetLife Investment Management LLC grew its position in shares of Harmony Biosciences by 46.7% during the first quarter. MetLife Investment Management LLC now owns 13,697 shares of the company’s stock worth $666,000 after acquiring an additional 4,360 shares during the last quarter. Institutional investors and hedge funds own 84.76% of the company’s stock.

Wall Street Analyst Weigh In

HRMY has been the topic of a number of research reports. Needham & Company LLC restated a “buy” rating and set a $67.00 target price on shares of Harmony Biosciences in a research report on Monday, April 17th. TheStreet lowered shares of Harmony Biosciences from a “b-” rating to a “c” rating in a research report on Tuesday, February 21st. Mizuho restated a “buy” rating and set a $60.00 target price on shares of Harmony Biosciences in a research report on Wednesday, March 29th. Cantor Fitzgerald raised their target price on shares of Harmony Biosciences from $71.00 to $75.00 in a research report on Wednesday, May 3rd. Finally, Bank of America began coverage on shares of Harmony Biosciences in a research report on Thursday, April 20th. They issued a “neutral” rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.89.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $35.64 on Tuesday. The firm has a market capitalization of $2.14 billion, a P/E ratio of 11.50, a PEG ratio of 0.51 and a beta of 0.45. Harmony Biosciences Holdings, Inc. has a one year low of $29.81 and a one year high of $62.08. The company’s fifty day moving average is $35.23 and its two-hundred day moving average is $46.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 4.85 and a current ratio of 4.90.

Harmony Biosciences (NASDAQ:HRMY – Get Rating) last issued its earnings results on Tuesday, February 21st. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.54 by $0.47. The company had revenue of $128.31 million for the quarter, compared to analyst estimates of $127.73 million. Harmony Biosciences had a net margin of 40.19% and a return on equity of 49.67%. Analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.4 EPS for the current fiscal year.

Harmony Biosciences Company Profile

(Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.